Low Sodium Diet, Vitamin D, or Both for RAASi-Resistant, Residual, Proteinuria in CKD? The ViRTUE Trial Points the Way Forward but Is Not the Last Word.
作者信息
Goldsmith David, Thadhani Ravi I
机构信息
Division of Nephrology, Guy's and St. Thomas' Hospitals, London, United Kingdom.
Molecular and Clinical Sciences Research Institute, St. George's, University of London, London, United Kingdom.
出版信息
J Am Soc Nephrol. 2017 Apr;28(4):1016-1019. doi: 10.1681/ASN.2016121321. Epub 2017 Feb 28.
Abstract
摘要
相似文献
1
Low Sodium Diet, Vitamin D, or Both for RAASi-Resistant, Residual, Proteinuria in CKD? The ViRTUE Trial Points the Way Forward but Is Not the Last Word.低钠饮食、维生素D，或两者兼用对慢性肾脏病中肾素-血管紧张素-醛固酮系统抑制剂抵抗的残余蛋白尿有效？ViRTUE试验指明了前进的方向，但并非最终定论。
J Am Soc Nephrol. 2017 Apr;28(4):1016-1019. doi: 10.1681/ASN.2016121321. Epub 2017 Feb 28.
2
Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial.维生素D受体激活和饮食限钠对慢性肾脏病残余蛋白尿的影响：ViRTUE-CKD试验
J Am Soc Nephrol. 2017 Apr;28(4):1296-1305. doi: 10.1681/ASN.2016040407. Epub 2016 Nov 17.
3
Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): rationale and study protocol.维生素 D 受体激动剂和饮食钠限制减少慢性肾脏病的残余尿白蛋白排泄（ViRTUE 研究）：基本原理和研究方案。
Nephrol Dial Transplant. 2016 Jul;31(7):1081-7. doi: 10.1093/ndt/gfv033. Epub 2015 Mar 4.
4
Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels.肾脏保护作用的肾素-血管紧张素-醛固酮系统（RAAS）抑制并不影响肾功能较差与血浆醛固酮水平较高之间的关联。
BMC Nephrol. 2017 Dec 20;18(1):370. doi: 10.1186/s12882-017-0789-x.
5
A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria.一项关于联合使用骨化三醇和麦角钙化醇与单独使用麦角钙化醇治疗伴有蛋白尿的慢性肾脏病的双盲、随机、安慰剂对照试验。
BMC Nephrol. 2017 Jan 14;18(1):19. doi: 10.1186/s12882-017-0436-6.
6
Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.成纤维细胞生长因子 23 与肾素-血管紧张素-醛固酮系统阻断期间饮食钠限制的抗蛋白尿反应。
Am J Kidney Dis. 2015 Feb;65(2):259-66. doi: 10.1053/j.ajkd.2014.07.022. Epub 2014 Sep 30.
7
Plasma Vitamin D Level and Change in Albuminuria and eGFR According to Sodium Intake.根据钠摄入量的血浆维生素D水平以及蛋白尿和估算肾小球滤过率的变化
Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2119-27. doi: 10.2215/CJN.03830415. Epub 2015 Oct 8.
8
Dietary Salt Restriction in Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials.膳食盐限制在慢性肾脏病中的应用：一项随机临床试验的荟萃分析。
Nutrients. 2018 Jun 6;10(6):732. doi: 10.3390/nu10060732.
9
Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD.维生素D、蛋白尿、糖尿病肾病与慢性肾脏病的进展
Clin J Am Soc Nephrol. 2009 Sep;4(9):1523-8. doi: 10.2215/CJN.02010309. Epub 2009 May 28.
10
Vitamin D analogues to target residual proteinuria: potential impact on cardiorenal outcomes.靶向残余蛋白尿的维生素D类似物：对心肾结局的潜在影响。
Nephrol Dial Transplant. 2015 Dec;30(12):1988-94. doi: 10.1093/ndt/gfu404. Epub 2015 Jan 20.
引用本文的文献
1
Rationale and design of a placebo controlled randomized trial to assess short term, high-dose oral cholecalciferol on select laboratory and genomic responses in African Americans with hypovitaminosis D.评估短期大剂量口服胆钙化醇对非裔美国人维生素 D 缺乏症患者选择的实验室和基因组反应的安慰剂对照随机试验的原理和设计。
Contemp Clin Trials. 2018 Sep;72:20-25. doi: 10.1016/j.cct.2018.07.006. Epub 2018 Jul 18.
本文引用的文献
1
Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria.高血压患者的亚临床肾损伤：打开一扇观察心血管系统的肾脏之窗。聚焦微量白蛋白尿。
Adv Exp Med Biol. 2017;956:279-306. doi: 10.1007/5584_2016_85.
2
Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial.维生素D受体激活和饮食限钠对慢性肾脏病残余蛋白尿的影响：ViRTUE-CKD试验
J Am Soc Nephrol. 2017 Apr;28(4):1296-1305. doi: 10.1681/ASN.2016040407. Epub 2016 Nov 17.
3
Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade.与双重肾素-血管紧张素系统阻断相关的急性肾损伤的发病率、严重程度及转归
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1944-1953. doi: 10.2215/CJN.03470316. Epub 2016 Sep 27.
4
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.盐皮质激素受体拮抗剂对蛋白尿及慢性肾脏病进展的影响：一项系统评价与荟萃分析
BMC Nephrol. 2016 Sep 8;17(1):127. doi: 10.1186/s12882-016-0337-0.
5
Cardiovascular risk prediction in people with chronic kidney disease.慢性肾病患者的心血管风险预测
Curr Opin Nephrol Hypertens. 2016 Nov;25(6):518-523. doi: 10.1097/MNH.0000000000000265.
6
Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits.校准双重肾素-血管紧张素系统阻断对心脏和肾脏的影响——权衡风险与益处。
Int J Clin Pract. 2016 Jul;70(7):537-53. doi: 10.1111/ijcp.12803. Epub 2016 Jun 9.
7
Renin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead.慢性肾脏病中的肾素-血管紧张素-醛固酮系统阻断：当前策略与展望
Intern Emerg Med. 2016 Aug;11(5):627-35. doi: 10.1007/s11739-016-1435-5. Epub 2016 Mar 17.
8
Epidemiology of CKD Regression in Patients under Nephrology Care.肾脏病护理患者慢性肾脏病病情缓解的流行病学
PLoS One. 2015 Oct 13;10(10):e0140138. doi: 10.1371/journal.pone.0140138. eCollection 2015.
9
Surrogate endpoints in clinical trials of chronic kidney disease progression: moving from single to multiple risk marker response scores.慢性肾脏病进展临床试验中的替代终点：从单一风险标志物反应评分转向多风险标志物反应评分。
Curr Opin Nephrol Hypertens. 2015 Nov;24(6):492-7. doi: 10.1097/MNH.0000000000000159.
10
Endothelin in nondiabetic chronic kidney disease: preclinical and clinical studies.非糖尿病慢性肾脏病中的内皮素：临床前和临床研究
Semin Nephrol. 2015 Mar;35(2):176-87. doi: 10.1016/j.semnephrol.2015.03.002.
Zotero 插件